Suggested Readings

American College of Cardiology Scientific Sessions & Expo

March 2018; Orlando, Florida.

Cardiovascular outcomes with alirocumab after acute coronary syndrome: results of the ODYSSEY Outcomes trial.

Steg P, et al. American College of Cardiology Scientific Sessions & Expo; March 2018; Orlando, FL. Late-Breaking Clinical Trial Session 401-08.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, et al. Am Heart J. 2014;168(5):682-689.

Evolocumab and clinical outcomes in patients with cardiovascular disease.

Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

Sabatine MS, et al. Am. Heart J. 2016;173:94-101.

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Goldberg AC, et al. J Clin Lipidol. 2011;5(suppl 3):S1-S8.

Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Robinson JG. J Manag Care Pharm. 2013;19(2):139-149.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Robinson JG, et al. N Engl J Med. 2015;372(16):1489-1499.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Sabatine MS, et al. N Engl J Med. 2015;372(16):1500-1509.

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.

Zhang XL, et al. BMC Med. 2015;13(123):1-18.

Linked Resources

Clinical Practice Guidelines

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Stone NJ, et al. Circulation. 2014;129(25 suppl 2):S1-S45.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report.

Jacobson TA, et al. J Clin Lipidol. 2015;9(2):129-169.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Lloyd-Jones DM, et al. J Am Coll Cardiol. 2016;68(1):92-125.

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Lloyd-Jones DM, et al.J Am Coll Cardiol. 2017;70(14):1785-1822.

Recent Update to the US Cholesterol Treatment Guidelines A Comparison With International Guidelines.

Nayor M, Vasan RS. Circulation. 2016;133(18):1795-1806.

Clinical Assessment Tools

ASCVD Risk Estimator

A companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk and the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Goff DC, et al. J Am Coll Cardiol. 2014;633(25 Pt B):2935-2959 and Goff DC, et al. Circulation. 2014:129(25 suppl 2):S49-S73).

Reynolds Risk Score

A framework for calculating heart and stroke risk for women and men (Ridker PM, et al. JAMA. 2007;297(6):611-619).

Patient Resources

Centers for Disease Control and Prevention

Educational materials for patients with high cholesterol.

American Heart Association

Resources on managing hyperlipidemia by controlling cholesterol and triglycerides.

The FH Foundation

A patient-centered nonprofit organization dedicated to education, advocacy, and research on familial hypercholesterolemia (FH).

Related activities
SnapShot 
0.50 CME

Hot Topics in Dyslipidemia

From the 2018 American College of Cardiology Scientific Sessions

Faculty: Deepak L. Bhatt, MD, MPH; Christopher P. Cannon, MD
Release: 04/04/2018
Expiration: 04/04/2019
SnapShot 
0.25 CME/CE

Individualizing LDL-C Targets in High-Risk Patients

Module 2

Faculty: Christie M. Ballantyne, MD, FACP, FACC; Marc S. Sabatine, MD, MPH
Release: 08/15/2018
Expiration: 08/14/2019
SnapShot 
0.25 CME/CE

Novel Nonstatin LDL-C Targets in High-Risk Patients

Module 3

Faculty: Christie M. Ballantyne, MD, FACP, FACC; Marc S. Sabatine, MD, MPH
Release: 08/14/2018
Expiration: 08/14/2019
SnapShot 
0.25 CME/CE

Long-term Cardiovascular Outcomes Trials With PCKS9 Inhibitors

Module 4

Faculty: Christie M. Ballantyne, MD, FACP, FACC; Marc S. Sabatine, MD, MPH
Release: 08/13/2018
Expiration: 08/14/2019
SnapShot 
0.25 CME/CE

Collaborating with Patients to Reduce Long-Term Hypercholesterolemia Risks

Module 5

Faculty: Deepak L. Bhatt, MD, MPH; Christopher P. Cannon, MD;
Release: 10/22/2018
Expiration: 10/22/2019
SnapShot 
0.25 CME/CE

Tailored Lipid-Lowering Regiments for Specific Very High-Risk Profiles

Module 6

Faculty: Christopher P. Cannon, MD; Sergio Fazio, MD, PhD
Release: 10/22/2018
Expiration: 10/22/2019
SnapShot 
0.25 CME/CE

Pharmacoeconomic Outcomes of Suboptimal LDL-C Management

Module 7

Faculty: Deepak L. Bhatt, MD, MPH; Sergio Fazio, MD, PhD
Release: 10/22/2018
Expiration: 10/22/2019
SnapShot 
1.00 CME/CE

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Faculty: Christie M. Ballantyne, MD, FACP, FACC; Deepak L. Bhatt, MD, MPH; Christopher P. Cannon, MD; Sergio Fazio, MD, PhD
Release: 11/28/2018
Expiration: 11/28/2019